150,000 Shares in Cellebrite DI Ltd. $CLBT Acquired by Guardian Point Capital LP

Guardian Point Capital LP bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 150,000 shares of the company’s stock, valued at approximately $2,704,000. Cellebrite DI makes up about 0.8% of Guardian Point Capital LP’s investment portfolio, making the stock its 12th biggest position. Guardian Point Capital LP owned 0.06% of Cellebrite DI at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellebrite DI by 16.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after purchasing an additional 24,881 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Cellebrite DI by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock worth $5,029,000 after purchasing an additional 43,898 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Cellebrite DI by 6.4% in the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after purchasing an additional 209,473 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of Cellebrite DI during the second quarter valued at approximately $341,000. Finally, Marshall Wace LLP acquired a new stake in shares of Cellebrite DI during the second quarter valued at approximately $4,472,000. 45.88% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 13,269 shares of company stock worth $169,592 over the last quarter. Insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of recent analyst reports. Needham & Company LLC cut their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. DA Davidson initiated coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Price Performance

CLBT stock opened at $12.81 on Wednesday. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The company’s 50 day simple moving average is $13.19 and its 200-day simple moving average is $14.98. The firm has a market capitalization of $3.20 billion, a P/E ratio of 45.75, a P/E/G ratio of 1.62 and a beta of 1.17.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.